[Novel anticoagulants for stroke prevention in atrial fibrillation].
The most frequent cardiac arrhythmia and main cause for cardio-embolic stroke is atrial fibrillation. Prophylaxis for thrombembolic events is performed regarding individual risk of patients with either ASS or vitamin-K-antagonists. Efficacy and safety of oral anticoagulation is limited by a narrow therapeutical range as well as by inter- and intraindividual variability of INR-values due to genetic disposition, differences in alimentation, dosage errors, rare control of INR-levels and drug-interactions. New oral anticoagulants with different mechanisms of action may be a promising therapeutic option in future. This review addresses the new anticoagulants Apixaban, Rivaroxban and Dabigatranetexilat with the design and as available the results of the corresponding phase-III-trials in atrial fibrillation (ARISTOTLE, ROCKET-AF, RE-LY).
Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes. magnus@baumhaekel.de
M
M
Baumhäkel
S H
SH
Schirmer
M
M
Böhm
D000925:Anticoagulants / Q000145:classification / Q000627:therapeutic use*; D000991:Antithrombins / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000150:complications* / Q000188:drug therapy; D001384:Azetidines / Q000627:therapeutic use; D001562:Benzimidazoles / Q000627:therapeutic use; D001596:Benzylamines / Q000627:therapeutic use; D017326:Clinical Trials, Phase III as Topic; D000069604:Dabigatran; D065427:Factor Xa Inhibitors; D005343:Fibrinolytic Agents / Q000145:classification / Q000627:therapeutic use*; D006801:Humans; D009025:Morpholines / Q000627:therapeutic use; D011720:Pyrazoles / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use; D011728:Pyridones / Q000627:therapeutic use; D000069552:Rivaroxaban; D020521:Stroke / Q000517:prevention & control*; D013876:Thiophenes / Q000627:therapeutic use; D013923:Thromboembolism / Q000517:prevention & control*
D000925:Anticoagulants; D000991:Antithrombins; D001384:Azetidines; D001562:Benzimidazoles; D001596:Benzylamines; D065427:Factor Xa Inhibitors; D005343:Fibrinolytic Agents; D009025:Morpholines; D011720:Pyrazoles; D011725:Pyridines; D011728:Pyridones; D013876:Thiophenes; C522181:apixaban; C426686:ximelagatran; D000069552:Rivaroxaban; D000069604:Dabigatran